New Metrics for Economic Evaluation in the Presence of Heterogeneity: Focusing on Evaluating Policy Alternatives Rather than Treatment Alternatives-Reference-Cited by-同舟云学术

New Metrics for Economic Evaluation in the Presence of Heterogeneity: Focusing on Evaluating Policy Alternatives Rather than Treatment Alternatives

Published:2017-04-25 Issue:8 Volume:37 Page:930-941
ISSN:0272-989X
Container-title:Medical Decision Making
language:en
Short-container-title:Med Decis Making

Author:

Kim David D.¹²,Basu Anirban¹²

Affiliation:

1. Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA (DDK)

2. Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, and the Departments of Health Services and Economics University of Washington, Seattle, WA, USA (AB)

Publisher

SAGE Publications

Subject

Health Policy

Link

http://journals.sagepub.com/doi/pdf/10.1177/0272989X17702379

Reference27 articles.

1. Foundations of Cost-Effectiveness Analysis for Health and Medical Practices

2. Cost-Effectiveness in Health and Medicine

3. The NICE Cost-Effectiveness Threshold

4. Economics of individualization in comparative effectiveness research and a basis for a patient-centered health care

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in Addressing Patient Heterogeneity in Economic Evaluation: A Review of the Methods Literature;PharmacoEconomics;2024-04-27

2. Evaluating Policies of Expanding Versus Restricting First-Line Treatment Choices: A Cost-Effectiveness Analysis Framework;Value in Health;2024-04

3. Does Clinical Evidence of Heterogeneity Impact Treatment Selection? A Case Study of Abiraterone for Metastatic Prostate Cancer;Journal of the National Comprehensive Cancer Network;2022-10

4. Tools for the Economic Evaluation of Precision Medicine: A Scoping Review of Frameworks for Valuing Heterogeneity-Informed Decisions;PharmacoEconomics;2022-07-27

5. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework;Health Technology Assessment;2021-12